GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Acuta Capital Partners

Cormorant Asset Management

RA Capital Management

RTW Investments

Logos Capital

Biotechnology Value Fund

Boxer Capital

BVF Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Verition Fund Management

GH Research plc

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

https://lnkd.in/eEJUSZpQ

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue					315K -
gross profit					-315K -
selling and marketing expenses
general and administrative expenses	14K -	108K 671.43%	6.55M 5,962.04%	10.07M 53.81%
selling general and administrative expenses	14K -	108K 671.43%	6.55M 5,962.04%	10.07M 53.81%	11.12M 10.43%
research and development expenses	296K -	338K 14.19%	8.55M 2,430.47%	20.48M 139.49%	29.79M 45.41%
other expenses
cost and expenses	310K -	446K 43.87%	15.10M 3,285.65%	30.55M 102.34%	41.22M 34.91%
operating expenses	310K -	446K 43.87%	15.10M 3,285.65%	30.55M 102.34%	40.91M 33.88%
interest expense			9K -	-8.10M 90,077.78%	723K 108.93%
ebitda	-310K -	-445K 43.55%	-15.08M 3,288.99%	-37.73M 150.18%	-40.91M 8.42%
operating income	-310K -	-446K 43.87%	-15.10M 3,285.65%	-30.55M 102.34%	-41.22M 34.91%
depreciation and amortization		1K -	19K 1,800%	-7.18M 37,868.42%	315K 104.39%
total other income expenses net			5.90M -	8.10M 37.30%	5.63M 30.43%
income before tax	-310K -	-446K 43.87%	-9.20M 1,963.23%	-22.46M 144.03%	-35.59M 58.47%
income tax expense			9K -	-15.32M 170,333.33%	-1 100.00%
net income	-310K -	-446K 43.87%	-9.21M 1,965.25%	-7.13M 22.54%	-35.59M 398.77%
weighted average shs out	28M -	28.36M 1.28%	43.68M 54.03%	51.98M 19.00%	52.02M 0.08%
weighted average shs out dil	28M -	28.36M 1.28%	43.68M 54.03%	51.98M 19.00%	52.02M 0.08%
eps	-0.01 -	-0.02 41.44%	-0.21 1,237.58%	-0.14 33.33%	-0.68 385.71%
epsdiluted	-0.01 -	-0.02 41.44%	-0.21 1,237.58%	-0.14 33.33%	-0.68 385.71%

COM:GHRES

GH Research PLC

Last Close

9.62

22/11 21:00

Market Cap

591.56M

Beta: -

Volume Today

61.64K

Avg: -

Preview